Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conference, hosted by the...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicatin...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikelihood...

Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40 subject...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters containi...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two group...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction ofLesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation today announced the presentation ofpositive results from a clinical trial examining the safety andefficacy of pilot process HspE7, an investigational therapeuticvaccine for human papillomavirus (...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 06, 2007/PRNewswire/ -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") andLantibio, Inc. ("Lantibio") today announced positive final resultsfrom their placebo controlled, double-blinded Phase II clinicalstudy of Moli1901, an experimental compound to treat cysticfibrosis ("CF"). Moli1901 is being developed by AOP Orphan inEurope under a licensi...

Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced CellTechnology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blindrats was noted in Scientific American's March 2007 issue as thelead story of its News Scan section. The full text of the article,which notes Advanced Cell's ability to "coax embryonic stem cellsto turn into transplantable retinal pigment epithelial (RPE)tissue," is...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...
[next]
(Date:11/14/2018)... N.J. (PRWEB) , ... November 14, 2018 , ... PAINWeekEnd ... in Maryland, will be an educational and exciting program providing busy clinicians and allied ... pain. , According to the National Institute on Drug Abuse, Maryland is among ...
(Date:11/14/2018)... , ... November 14, 2018 , ... The Austin-area ... New Year approaches, it’s time to pull out the healthcare plan paperwork to review ... plan or sponsored by an employer, most people can benefit by taking a few ...
(Date:11/13/2018)... ... 2018 , ... A survey by the publishers of ADC Review | ... therapies reached U.S. $ 4 billion. Approximately forty-five percent of this market included Antibody-drug ... (including ADCs) is expected to grow significantly, to U.S. $ 17 billion by 2023. ...
(Date:11/13/2018)... ... November 13, 2018 , ... As California deals with ... the clock to help policyholders through the recovery process. , “The insurance ... Pettibone, vice president of state affairs, western region. “We urge policyholders to heed ...
(Date:11/13/2018)... , ... November 13, 2018 , ... ... with corporate partners GE Global Research and Acoustic MedSystems Inc., have received a ... National Cancer Institutes’ (NCI) Academic-Industrial Partnership program, to continue development of an innovative ...
Breaking Medicine News(10 mins):
... Within weeks, the University of Michigan will ... provide a springboard for new discoveries, job creation and ... U-M,s future.U-M,s purchase of the former Pfizer pharmaceutical research ... be completed on June 16, said executive vice president ...
... Sponsored by Courage Center St. Croix and EveryKid MobilityMINNEAPOLIS, May ... of passage for every kid! Come to Courage Center St. ... to test ride adaptive bikes designed to make this dream ... St. Croix is located at 1460 Curve Crest Blvd., Stillwater.Many ...
... Offit Kurman, one of the fastest growing legal services ... with expansion into Bethesda, MD. As of July ... will join the aggressively expanding Offit Kurman firm. ... to privately held businesses in the mid-Atlantic area, adding ...
... IQAir Recognized as the Most Effective Room Air Purifier ... -- IQAir North America, Inc., the industry ... cleaning products, announced today the IQAir HealthPro Plus earned ... Seal of Approval. In an independent series of ...
... Pathfinders, a program designed to care for the whole person ... help women with terminal cancer cope and improved their quality ... the Duke Comprehensive Cancer Center. , "The program helped improve ... to six months after diagnosis among women with metastatic breast ...
... Smith & Nephew,s (NYSE: SNN ; ... its first contribution to the Orthopaedic Research and Education ... & Nephew announced in January it entered into a ... serve as an independent grant-making organization for Smith & ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products:
(Date:11/13/2018)... ... November 13, 2018 , ... ActivePDF ... its commitment to supporting charitable causes through a recent partnership with California ... event called “Spooktacular Social,” an over 300-person social gathering for adults with autism ...
(Date:11/13/2018)... NASHVILLE, Tenn. (PRWEB) , ... November 13, 2018 ... ... Have Protective Effect After Heart Failure , Patients who have previously undergone weight-loss ... dying in half compared to those who did not have surgery, according to ...
(Date:11/13/2018)... ... November 13, 2018 , ... Citus Health, a digital ... made available a new video chat solution to enable patients and staff with ... Health Platform adding another layer of patient engagement capability to its robust HIPAA ...
Breaking Medicine Technology:
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
... DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc. ... and dermatology, today announced that a catheter,treated ... biofilm,formation in a 21 day study., In ... soaked daily in a phosphate-suffered solution along ...
Cached Medicine Technology: